AXL and neoplasm: Therefore, the cell line established in vitro from this osimertinib-resistant tumor xenograft has been used to test the efficacy of the combined inhibition of AXL, by the use of foretinib, and SMO, by the use of sonidegib, on cell proliferation, migration and invasion capabilities of resistant cells, in the presence or absence of osimertinib (Figure 6B).